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1. Introduction
Celiac disease (CD) is an autoimmune condition affecting the small intestine, triggered by the
ingestion of gluten, the protein fraction of wheat, barley, and rye. There is a strong linkage
between CD and HLA-DQ2 and HLA-DQ8 haplotypes. As in other autoimmune diseases, CD
results from of an immune response to self-antigens, leading to tissue destruction plus the
production of autoantibodies and has a complex pattern of inheritance with influence from
both environmental as well as additive and non-additive genetic factors [1, 2]
A significantly increased prevalence of other autoimmune diseases has been reported in
individuals with CD and their first-degree relatives as compared to controls. This chapter
provides an overview of the pathogenesis of CD and reviews the literature regarding associ‐
ations between CD and other autoimmune diseases, including the potential effects of gluten-
free diet therapy on the prevention or amelioration of associated diseases. It has been
speculated that these associations might share a pathogenic basis that involves the same
environmental triggers, genetic predisposition, compromise of the intestinal barrier secondary
to the failure of tight junctions, leading to greater permeability of the intestine, and perhaps
mechanisms yet to be identified [1, 2].
2. Autoimmune disorders
The decline in physiological tolerance against “self” antigens gives rise to autoimmune
disorders. While various mechanisms might participate in this process, faulty regulation of B-
cell and T-cell activation as well as of inflammation pathways are plausible [3]. Predisposition
to autoimmune diseases has been related to genetic, epigenetic, and environmental factors.
With modern genetic-analysis techniques, our grasp of autoimmunity is steadily improving.
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To date, over 30 genome-wide association studies (GWAS) have examined an array of
autoimmune diseases (AID) while studies have identified hundreds of common variants that
represent protection or risk [4].
The genetic bases of autoimmunity are just starting to be uncovered, while several suscepti‐
bility genes have been identified in the most common autoimmune diseases. In addition,
structural variants (insertion/ deletion polymorphisms, copy number variations, etc.) are also
likely to play a significant role in determining susceptibility to autoimmune disorders [3-4].
Although on the genetic level, immune-related diseases still differ, e.g. in the number of
disease-susceptibility loci, the effect sizes associated with each locus, and the environmental
factors involved in the various diseases [5], there is clearly a remarkable overlap of suscepti‐
bility factors between various immune-related diseases [6-8]. The complex inheritance pattern
implies the involvement of several genes. Despite that the same genes are unlikely to account
for susceptibility to all autoimmune disorders, one gene complex (major histocompatibility
complex, MHC, in the human leukocyte antigen, HLA) has invariably been involved as a key
genetic risk factor and might explain why the autoimmune diseases co-exist [9].
This overlap clearly implies the involvement of shared pathways in multiple autoimmune
diseases and, most importantly, suggests that general treatment modalities might be feasible
for some immune-related diseases [9].
3. Celiac disease as an autoimmune disorder
Celiac disease (CD) is one of the best-understood immune-related diseases. CD is frequent
with a prevalence of about 1:100, and it occurs selectively in individuals expressing HLA-DQ2
or HLA-DQ8. The prevalence of CD in the western world is probably underestimated, since
not all cases of CD are symptomatic and thus go undiagnosed [1]. As in patients with organ-
specific autoimmune disorders, patients with CD have autoantibodies and suffer from the
destruction of a specific tissue-cell type by CD8+ T cells [2, 10]. The presence of highly disease-
specific transglutaminase 2 (TG2)-specific autoantibodies allows the diagnosis of the disease.
These autoimmune features require the presence of gluten, and HLA-DQ2- or HLA-DQ8-
restricted gluten-specific CD4+ T-cell responses have a central role in disease pathogenesis [10,
11]. On the basis of CD, it bears considering that exogenous antigens may drive autoimmune
disorders.
The pathogenesis of CD reveals a complex interplay between environmental factors, genetics,
the adaptive and innate immune systems, and the presence of autoantigens, in a process which
has still not been fully elucidated.
It is a multifactorial disease caused by many different genetic factors acting in concert with
non-genetic causes. Similar to other autoimmune diseases, CD is a polygenic disorder for
which the MHC locus is the single most important genetic factor. The MHC locus accounts for
40 to 50% of the genetic variance in the disease. A genetic association between CD and the
HLA class II genes in the major histocompatibility complex (MHC) has been documented [12,
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13]. Although the HLA component of CD susceptibility is well characterized, little is known
about the possible role of other genes than HLA [14–16]. Recently, various non-MHC genes
have been found to be susceptibility factors. To date, researchers have described 39 loci having
57 independent association signals [17]. Of these genes, many are associated with immunity,
especially with T-cell and B-cell function. All these loci together account for an estimated 14%
of all genetic variance of CD [17].
These non-HLA genes may be important determinants of disease susceptibility, as indirectly
shown by the high disease concordance rate in monozygotic twins (70%) compared with only
30% in HLA identical twins [18]. Mounting evidence suggests a genetic relationship between
the CTLA4 locus and various autoimmune disorders. CTLA4-Ig blockage of T-cell activation
may determine some (though not all) immunological aspects of human CD [19]. A French case-
control study [20] reported evidence of association between CD and CTLA4 exon 1 polymor‐
phism. Also, significant evidence for linkage to CD was found in a recent study on family-
based linkage of the CTLA4 region, as well as 39UTR polymorphisms and exon 1 [21].
More than 60% of CD-associated susceptibility loci are shared with at least another autoim‐
mune condition such as type-1 diabetes and rheumatoid arthritis [22], suggesting common
pathogenic mechanisms. In particular, the recognition of peptides by HLA molecules,
posttranslational modifications required for optimal peptide binding, and immune mecha‐
nisms leading to tissue damage have been found [23].
One of the most important factors triggering CD is dietary gluten, a storage protein present in
wheat and related grains (hordein in barley, secalin in rye, and avedin in oats). CD is an
excellent model for studying the contribution of genetic factors to immune-related disorders
because: (1) the environmental triggering factor is known (gluten); (2) as in other autoimmune
diseases, in which specific HLA types (HLADQA1 and HLA-DQB1 are critically involved; (3)
there is involvement of non-HLA disease-susceptibility loci, many of which are shared with
other autoimmune diseases; (4) there is an elevated incidence of other immune-related diseases
both in family members and individuals; and (5) both the innate and the adaptive immune
responses play a role in CD [24, 25].
The tendency for multiple autoimmune disorders to occur over the lifetime of a CD patient
has been well described. The co-existence of autoimmune diseases with CD is striking, and
there is an association of the disease with type-1 diabetes, Sjögren’s syndrome, autoimmune
thyroid disorders, connective-tissue diseases and IgA deficiency. The role of protein complexes
formed between exogenous and endogenous proteins in the formation of autoantibodies, and
a CD8+ T cell response directed against altered-self and mediated by NK receptors in CD is an
autoimmune reaction [8].
3.1. Pathogenesis
The main factors in CD pathogenesis include defective antigen processing by epithelial cells,
along with the intrinsic properties of gliadins in addition to the individual’s HLA-DQ
haplotype [26]. This disorder is closely related to HLA class-II genes which map to the DQ
locus. CD has been associated with the expression of both HLA-DQ2 and HLA-DQ8 expression
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[27, 28]. A number of studies [29] have shown that most CD patients carry DQ2 (DQA1*05/
DQB1*02), while the rest display an association with DQ8 (DQA1*0301/DQB1*0302). These
HLA genes collectively represent as much as 50% of the genetic risk of developing CD. Studies
on independent genome-wide linkage have found scant overlap among linkage regions, except
for the HLA region on chromosome 6p21. According to linkage studies, besides the HLA
region, the two likeliest regions are 19p13 and 5q32 [30-32].
The polymorphisms associated with autoimmune diseases appear to be primarily in genes that
have immune functions. These polymorphisms have presumably evolved for their advantages
in combating pathogens. These polymorphisms, in the presence of foreign antigen gluten, may
also help shape the immune response [33].
Gliadin peptide presentation and T-cell activation are critical events in the pathogenesis of CD.
The toxic effects of these prolamins include the reduction of F-actin, inhibition of cell growth,
premature cell death, the rearrangement of the cytoskeleton, and increased small-intestine
permeability [34].
Gastric, intestinal, and pancreatic enzymes do not fully digest gluten peptides in individuals
with CD. In these patients, a 33-mer peptide which has been isolated and has been identified
as being the prime trigger of inflammation in reaction to gluten [35]. This peptide reacts with
tissue transglutaminase (tTG), which is the main CD autoantigen, by which specific glutamine
residues of gluten are deamidated to glutamic acid. [12, 36]. Antigen-presenting cells that
express molecules of HLA-DQ2 and HLA-DQ8 show greater affinity for deamidated peptides.
Afterwards, as the immunogenic peptides generated bind to HLA molecules, peptide com‐
plexes form and are capable of activating host-gluten-specific CD4+ T cells found in the lamina
propria. When these T cells are activated, a number of cytokines are produced, in turn
promoting inflammation and damage to the small-intestine villi from metalloproteinases
released by inflammatory cells and fibroblasts [35, 29]. Activated gluten-specific CD4+ T cells
are also capable of stimulating B cells to produce anti-gluten and anti-TG2 antibodies. It is
believed that the IFN-gamma production from these gluten-specific T cells may be the main
cause of mucosal intestinal lesion [35, 12]. Furthermore, shifts in intestinal permeability,
secondary to changes in tight junctions or in food-antigen processing, have recently been
associated also with a loss of gluten tolerance [29].
3.2. Clinical presentation
The clinical profile of CD is extremely varied. In children, the disorder is often reflected in
anemia, abdominal distension, chronic diarrhea, steatorrhea, delayed puberty, and short
stature. Common adult symptoms include abdominal distention and pain, chronic diarrhea,
malabsorption, and general weakness [9]. Nevertheless, many individuals have few or no
gastrointestinal symptoms, but present features such as neurological problems, anemia,
osteoporosis, dermatitis herpetiformis, and fertility problems among others [29, 12]. Therefore,
instead of primarily a gastrointestinal malady, CD should be considered more as a multisystem
disorder. Whereas some non-intestinal symptoms of CD, e.g. osteoporosis or anemia, are due
chiefly to nutritional deficiencies resulting from mucosal injury, others imply a far more
complex relation to CD involving immunological as well as genetic factors.
Autoimmunity - Pathogenesis, Clinical Aspects and Therapy of Specific Autoimmune Diseases134
3.3. Diagnosis
CD can be diagnosed according to the current guidelines, given that an intestinal biopsy is the
only diagnostic procedure with broad consensus. CD diagnosis should follow the criteria laid
out by the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition
(NASPGHAN) or the European Society for Paediatric Gastroenterology and Nutrition
(ESPGAN) [37].[38]. Figure 2 summarizes CD diagnosis.
3.4. Immune (oral) tolerance
The intestinal tract is the major immunological organ of the human body and plays an essential
role in the induction of oral tolerance. Given that immunologically mediated reactions to foods
can affect almost all organ systems, some extrinsic factors, such as gluten, can perturb the
immune regulation in autoimmune disorders. The immune system of the intestine is exposed
to innumerable antigens from foods, and endogenous as well as exogenous microbes [39]. Oral
tolerance involves a lack of immune responsiveness towards food and bacterial antigens of
the gut flora. Many mechanisms at the cellular and molecular levels participate in regulating
this basic aspect of the intestinal immune system [40].
Figure 1. Schematic representation of CD pathogenesis.(Re-drawn of Sollid LM et al. Nature Reviews Immunology 13,
294-302. 2013)
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The most widespread food-sensitivity pathology in humans, CD results from defective
immune tolerance (oral tolerance) to gluten (wheat) and the prolamin (rye and barley).
Researchers have identified numerous gluten peptides that gut T cells recognize [41]. A major
event in the CD pathogenesis involves the activation of gluten-reactive T cells. A high
percentage of intraepithelial T cells that bear a gamma-delta chain of antigenic T-cell receptors
(γδ IEL) characterizes the mucosa in CD patients [42].
Figure 2. Algorithm for the diagnosis of celiac disease (Re-drawn of Mayo Foundation for Medical Education and Research
(MFMER)
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When ingested, the agent that triggers the disorder, gliadin, may penetrate the epithelial
barrier to trigger a harmful immune response mediated by T cells. Immature dendritic cells,
having characteristically low MHC class-II expression as well as co-stimulatory molecules, can
modulate tolerance apparently by inducing Treg cells (T regulatory cells) [43]. Furthermore,
Treg-cell-released IL-10 can mediate the activity of immature dendritic cells, inhibiting their
differentiation, and thus locally favoring the presence of ‘‘tolerizing dendritic cells’’ [44].
Anergy of effector T cells is induced by IL-10-modulated dendritic cells through an as yet
unknown process that requires contact between cells.
The immune-response shift towards tolerance or immunity is determined by the maturation
stage and functional aspects of the dendritic cells. The unresponsiveness stage of immature
dendritic cells can be overcome with the participation of gliadin peptides by inducing the
functional and phenotypic maturation of dendritic cells, promoting more effective gliadin
peptide processing and presentation to specific T lymphocytes [45]
A mouse model that overexpressed IL-15 in the lamina propria, at amounts comparable to
those found in CD subjects, in cooperation with retinoic acid, was demonstrated to break oral
tolerance to dietary antigens, triggering the differentiation of inflammatory dendritic cells that
produce proinflammatory cytokines IL-12p70 and IL-23 and prompting the differentiation of
IFN-γ-producing T cells (TH1 immunity)[46]. Also, Type-I IFNs are upregulated in the
intestinal mucosa of subjects having active CD [47]. By activating dendritic cells, Type-I IFNs
promote TH1-type immunity, causing oral tolerance to be lost, and might be an alternative
pathway, triggering the loss of gluten tolerance.
Of special interest in CD is the expression of soluble HLA-G, as this molecule is key in immune-
tolerance induction. We suggest that in CD a greater expression of soluble HLA-G could help
to restore gluten tolerance. That is, HLA-G appears to interact with an inhibitory receptor (ILT),
leading to the development of tolerogenic dendritic cells, inducing immunosuppressive and
anergic T cells, and inhibiting dendritic-cell maturation/activation. Inflammatory stimuli and
cytokines tightly control the expression of ILT receptors in dendritic cells [48]. Torres MI et al.
found a correlation between higher levels of soluble HLA-G expression and CD associated
with other autoimmune diseases, this depending on a genetic link of these diseases through
HLA genes[48].
3.5. Autoimmune features of celiac disease
3.5.1. Autoantibodies
Untreated CD patients (on a wheat-containing diet) usually have higher levels of antibodies
against wheat gluten, several other food antigens, and autoantigens present in the mucosa. In
some autoimmune disorders, autoantibodies can specifically interfere with the biologic
activities of a specific antigen, while in others they can cause tissue injury by forming immune
complexes that activate the complement system. High titers of autoantibodies against tissue
transglutaminase 2 (TG2) in patient sera TG2-specific immunoglobulin A (IgA) is the most
characteristic aspect of CD and can be used to diagnose the disorder, reaching specificity and
sensitivity of almost 100%. Even subjects with negative serum TG2-specific antibodies still
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seem to produce these antibodies locally, as reflected by small-intestine deposits [49]. In the
small-intestine mucosa of untreated cases, it has in fact been demonstrated that, with CD,
roughly 10% of all plasma cells prove to be TG2-specific [50]. The anti-TG2 antibodies in CD
have been shown to be capable of interfering with TG2 activity and hamper the differentiation
of epithelial cells [51, 52]. In addition, anti-TG2 antibodies also reportedly increased the
permeability of epithelial cells in an intestinal cell line and activated monocytes on binding to
Toll-like receptor 4, perhaps contributing to gut injury [53].
In CD subjects, although autoantibodies are directed mainly against the activated Ca2+
(extracellular) form of TG2, calreticulin and actin antibodies also appear [54, 55]. Antibodies
to TG2 include IgA as well as IgG isotypes, whereas IgA antibodies are more specific than IgG
antibodies, and it is also though that this Ab is produced primarily in the mucosa of the
intestine [56]. A weak inhibitory effect of the antibodies on certain TG2-catalyzed reactions
has been reported [57, 58]. TG2 is involved in the formation of active TGF-β by the crosslinking
of the TGF-β binding protein. Indirect inhibition of TGF-β activation can have broad effects,
including dysregulation of enterocytes and immune cells [59]. TG2 participates in the motility
as well as attachment of fibroblasts and monocytes through interactions with fibronectin and
integrins. The cause of CD villous atrophy could be the activity of TG2 autoantibodies
upsetting fibroblast and epithelial cell migration to the tips of the villi from the crypts [60].
Also, anti-TG2 antibodies may play a part in certain non-intestinal symptoms of CD, by
interacting with TG2, in addition to cross-reaction with other transglutaminases. Deposits of
anti-transglutaminase antibody have in fact been detected in the brainstem and cerebellum of
a patient showing cerebellar ataxia, and, in fact, gluten sensitivity. In certain idiopathic,
neurological, and psychiatric disorders, these antibodies proliferate, moving some researchers
to examine the potential of their cross-reactivity to neural antigens. In addition, anti-gliadin
antibodies reportedly bind to neural cells and also cross-react specifically with synapsin I [61].
3.5.2. Autoreactive intraepithelial lymphocytes
Leukocyte accumulation is common in autoimmune lesions. Similarly, leukocyte infiltration
occurs in CD lesions, in the lamina propria as well as in the epithelium [62]. CD8+ T cells, called
intraepithelial cytotoxic lymphocytes (IE-CTLs), predominantly infiltrate the epithelium. The
lamina propria shows greater density of different cell types, including antigen-presenting cells
(dendritic cells and monocytes), plasma cells, and CD4+ T cells.
Inhibitory and activating NKG2 natural killer (NK) receptors tightly regulate normal intrae‐
pithelial lymphocytes (IELs). These receptors recognize non-classical HLA molecules, which
are induced by IFN-β (HLA-E) and stress (MIC) exerted on epithelial cells of the intestine [63,
64]. CD, when untreated, characteristically has increasing density of proliferating TCRgd+
CD8_ CD4_ and TCRab+ CD8+ CD4_ cells in the villous epithelium, and this upregulates the
selectively activating NKG2 receptors [63, 65]. The upregulation of these NKG2 receptors
seems to be driven by IL-15, which is expressed by CD enterocytes [63, 66]. IL-15 seems to play
a critical role in the expansion of IELs [66], and in the induction of MIC molecules on intestinal
epithelial cells [67].
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As suggested by Sollid et al., in order for IE-CTLs to kill, need two independent but related
changes in the mucosa of the intestine: 1) a epithelium that is under stress and expresses high
IL-15 levels and non-classical MHC class-I molecules; and 2) activated gluten-specific CD4+ T
cells [68]. The way in which B-cell immunity, an adaptive anti-gluten T-cell immunity,
epithelial stress, and TG2 activation interact to determine the acquisition of a killer phenotype
by IE-CTLs remains to be elucidated.
3.5.3. Gluten-free diet and autoimmune disorders
Numerous papers have investigated the effect of CD treatment on the incidence and prognosis
of various autoimmune disorders [69]. A prospective study by Ventura et al. examining 90
adults with biopsy-proven CD determined the autoimmune antibody levels associated with
type-1 diabetes (glutamic acid decarboxylase, islet cell, anti-insulin) as well as autoimmune
thyroiditis (anti-thyroperoxidase); the examination was at CD diagnosis, and later, while on a
gluten-free diet (GFD), at intervals of as much as 2 years [70]. As all antibodies normalized
after 2 years without gluten intake, the authors concluded that a GFD was therapeutic against
related autoimmunity [70]. In a study by Cosnes et al., autoimmune-disease incidence proved
lower in the gluten-free-diet group compared to the gluten-intake group [71]. In the same
study, subjects with their first CD diagnosis at more than 36 years of age displayed a lower
cumulative risk of autoimmune disorders vs. subjects diagnosed at 16 to 36 or under 16 years
of age. The authors suggest that because CD manifests autoimmune dysregulation, celiac
patients who are older may be less prone to autoimmunity or CD [71]. Also, a later onset of
CD is related to greater intestinal-barrier integrity, thus diminishing antigen triggers in the
case of several autoimmune diseases. Other large-scale prospective studies would be helpful
to elucidate the way in which CD is related to other autoimmune conditions and to clarify the
possible influence that GFD exerts in this context. Further clarification of these relationships
would provide a fuller comprehension of specific disorders and of general autoimmunity.
4. Other autoimmune disorders associated
4.1. Associated autoimmune endocrine diseases
4.1.1. Type 1 Diabetes (T1D)
The association between CD and autoimmune insulin-dependent diabetes mellitus is one of
the most intensely studied relationships. The prevalence of CD among patients with type-1
diabetes has been estimated in approximately 4% and this risk is highest with diabetes onset
in childhood but also with a longer diabetes duration. It is known that T1D and CD both have
autoimmune origins [72]. Also, both disorders have been associated with the major histocom‐
patibility complex class-II antigen DQ2 encoded by the alleles, DQA1∗501 and DQB1∗201,
this offering a genetic basis in common for the expression of these disorders. A recent study
has also demonstrated that 7 shared non-HLAloci are associated with T1D as well as CD,
including a 32-bp insertion-deletion variant on chromosome 3p21, CTLA4 on chromosome
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2q33, SH2B3 on chromosome 12q24, PTPN2 on chromosome 18p11, TAGAP on chromosome
6q25, IL18RAP on chromosome 2q12, and RGS1 on chromosome 1q3 [73].
The ADA (American Diabetes Association) recommends screening T1D patients for CD and
placing all children with a confirmed diagnosis of CD on a gluten-free diet (GFD) [74]. The
screening of T1D patients for CD and a GFD is recommended by the NASPGHAN (the North
American Society for Pediatric Gastroenterology and Hepatology) for children without
symptoms but with an associated condition such as T1D. However, the ADA recognizes that
meager evidence exists for suggesting that a GFD provides short-term improvement of
diabetes. Furthermore, it remains to be clarified whether asymptomatic patients derive long-
or short-term health benefits, or both, from a GFD [75]. No clinical studies available have
monitored the natural progress of CD in asymptomatic patients, so that no beneficial effects
for asymptomatic CD and T1D patients strictly following a GFD are known. A GFD may affect
the lipid profile, HbA1c, glycemic values, insulin needs, and perhaps even diabetes compli‐
cations over the long term. Furthermore, GFD could alter, for example, growth rate, body-mass
index (BMI), height, and/or weight, although no consensus is available on the ultimate results
of such a diet. Hence, it is important to evaluate the impact of a GFD on metabolic control,
growth and nutritional status in children with TID and CD [76]
4.1.2. Thyroid diseases
In subjects having autoimmune thyroid disease (i.e. Hashimoto's thyroiditis and Grave's
disease), the CD rate reportedly accelerates, and its prevalence ranges between 2% and 7%.
Similar findings have been reported in CD patients, whose serological signs of autoimmune
thyroid disease (AITD) reached 26%, and in whom the detection of thyroid dysfunction
reached 10% of the cases, and thyroid disease risk was some 3-fold higher than in control.
Increased CD prevalence is known to occur in children and young adults who have AITD was
caused by enrichment with patients with other co-morbidities associated with CD. In the
absence of these co-morbidities or gastrointestinal symptoms, the prevalence of CD in AITD
may not be sufficient to justify serological screening for CD in patients with AITD. A preva‐
lence of positive tTG-IgA titers in patients with AITD was found to be higher than in a healthy
population and a greater prevalence (2.3%) of biopsy-confirmed CD was noted in patients
having AITD. [77]
The coexistence of CD and AITD has been explained by several mechanisms such as common
genetic predisposition and the association of both diseases with the gene-encoding CTLA4, a
gene causing susceptibility to thyroid autoimmunity. Several studies have suggested that
CTLA4 gene polymorphisms may be linked to autoimmune diseases, including TID, CD,
Addison’s disease, and autoimmune thyroid disorders [78, 79]. CTLA4 CT60 A/G polymor‐
phism was reported to be strongly associated with autoimmune thyroid disease (AITD and an
increased risk to develop a subsequent autoimmune disease in CD children [80].This study in
an Italian population showed that the risk of AITD in children with CD was substantially
modified by the CTLA4 CT60 A/G polymorphism, with the G allele in the homozygous state
being the high-risk genotype. In this sense, CTLA4 CT60 A/G polymorphism evaluation may
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be useful for stratifying the frequency of testing celiac children for antibodies indicative of
AITD [80].
4.2. Associated autoimmune liver disease
Autoimmune hepatitis (AIH), primary biliary cirrhosis (PBC) and primary sclerosing cholan‐
gitis (PSC) are all considered to be autoimmune liver diseases, in which the end result is
immune-mediated hepatocellular or hepatobiliary injury [81]. Clinical observations have
demonstrated a link between CD and all three major autoimmune liver diseases, the associa‐
tion with primary biliary cirrhosis (PBC) being greatest. Disturbances in mucosal immunity
may also be responsible for the hepatic manifestations of graft vs. host disease (GVHD) and
IgG4-associated autoimmune pancreatitis [81].
The breakdown of gut-liver axis equilibrium plays a central role in the development of immune
disorders involving the small bowel and liver in the context of genetic predisposition, and/or
gut inflammation. Comsmensals or pathogenic bacteria may stimulate immune responses that
fail to be suppressed by regulatory networks resulting in liver disease as a consequence of a
breakdown in self-tolerance driven by molecular-mimicry or activation of innate immune
pathways [82]. In celiac disease, immunologically active molecules generated from the cross-
linking between tTG and food/bacterial antigens reach the liver through the portal circulation
owing to the increased intestinal permeability and may contribute to triggering immune
hepatic damage. This enterohepatic pathway is facilitated by the aberrant expression of
adhesion molecules and chemokines that under normal conditions are restricted to either the
gut or liver.
Celiac disease and primary biliary cirrhosis have several features in common, such as greater
incidence in the female population, specific autoantibodies, and autoimmune comorbidities.
For both diseases, reciprocal screening is advised, because early diagnosis followed by
adequate treatment can enhance the outlook for such patients [82].
4.3. Associated autoimmune dermatological diseases
4.3.1. Dermatitis herpetiformis
Dermatitis herpetiformis (DH) is an inflammatory cutaneous disease with typical histopatho‐
logical and immunopathological findings, clinically characterized by intensely pruritic
polymorphic lesions with chronic relapse. DH patients reportedly undergo changes in the
small intestine; later, these abnormalities prove similar to those found in subjects with CD.
Currently this is considered more common than specific cutaneous manifestations of CD [83].
Although all DH patients present gluten sensitivity, a great majority are asymptomatic in terms
of digestive symptoms [84]. The intestinal biopsy performed in DH patients could reveal signs
of gluten sensitivity in 60% to 75%, ranging from normal-appearing epithelium to a flat mucosa
(Marsh I to III). DQ8 and HLA DQ2 prevalence is the same level as in CD, giving strength to
the idea that DH can be considered a cutaneous manifestation of CD. In fact HLA DQ2 is
expressed in some 90% of DH patients (approx. 20% of controls), the other 10% being DQ8. It
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is extremely rare to find patients who do not have the two predisposing HLA types [85]. These
two types typify this disease, and consequently a lifelong strictly gluten-free diet is the most
effective cure.
An additional worthwhile observation refers to CD patients who have DH. That is, these
patients not only have anti-TG2 antibodies but also have antibodies which target TG3, this
being a transglutaminase expressed only in the dermal papillae of patients with dermatitis
herpetiformis [86]
4.3.2. Psoriasis
Psoriasis is a chronic inflammatory disease characterized by well-demarcated, erythematous,
scaly plaques. Epidemiological and clinical studies suggest that psoriasis is associated with
celiac disease and celiac disease markers. Bhatia et al. [87] performed a meta-analysis to show
that psoriatic populations have an approximately 2.4-fold increased risk of elevated levels of
AGA compared with control subjects. These authors showed that IgA AGA antibodies were
positive in about 14% of patients with psoriasis vs. 5% of healthy control subjects. CD antibody
positivity has been positively correlated with psoriasis severity or psoriatic arthritis. Notably,
these psoriasis patients with high counts of CD antibodies did not necessarily show a corre‐
spondence to biopsy-confirmed diagnosis of celiac disease [87].
The pathogenesis of psoriasis and celiac disease involves the interplay among multiple gene-
susceptibility loci, the immune system, and various environmental factors and may involve
shared biological mechanisms. Genome-wide association studies of psoriasis and CD have
revealed that these two diseases share genetic-susceptibility loci at 8 genes, including at
TNFAIP3, RUNX3, ELMO1, ZMIZ1, ETS1, SH2B3, SOCS1, and UBE2L3. [88-90]. Adaptive and
innate immune responses are regulated by these genes. Despite that autoantibody formation
that typifies the Th2 axis is associated with CD, immunological studies of CD show that
gamma-delta T cells, Th17 cells, Th1 cells, and natural killer-like cells have key importance in
disease pathogenesis [91-94]. Similarly, psoriasis has been related to gamma-delta T cells, Th17
cells, and T helper (Th1) cells. Further hypotheses that link CD to psoriasis involve greater
intestinal permeability under both conditions, and the proposal that, in patients with CD,
vitamin-D deficiency can provoke psoriasis [95-97].
Regarding the benefit  of  a  GFD in patients  with psoriasis,  some case  reports  showed a
decrease in serologic markers of celiac disease after GFD and a significant reduction in the
Psoriasis Area Severity Index score. These case reports documented resolution of psoria‐
sis after GFD [98].
4.4. Associated rheumatological disorders and connective-tissue diseases
4.4.1. Systemic lupus erythematosus
Systemic lupus erythematosus (SLE) is a multisystem disorder with manifestations including
rash, arthritis, cytopenia, and renal disease. Some case reports have suggested the association
between CD and SLE. Patients with CD were at a 3-fold increased risk of SLE compared to the
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general population. Although this excess risk remained more than 5 years after CD diagnosis,
absolute risks were low. SLE is a complex autoimmune disease characterized by dysregulated
interactions between autoreactive T and B lymphocytes and the development of antinuclear
antibodies [99].
This is striking because both disorders share the human leukocyte HLA-B8 and HLA-DR3
histocompatibility antigens, and a variety of antibodies including the detection of tTG IgA as
well as antinuclear and anti-stranded DNA antibodies [100]. Picceli et al. found a significantly
higher frequency of anti-endomysium antibodies (IgA-EmA) in SLE patients than in controls,
although the titers of antibodies were predominantly low [101].
4.4.2. Rheumatoid arthritis
Celiac disease (CD) and rheumatoid arthritis (RA) are two autoimmune diseases characterized
by distinct clinical features but increased co-occurrence in families and individuals. In fact,
rheumatoid arthritis shares many major features that have been identified in CD, such as HLA
association, T-cell infiltration in target organs, disease-specific autoantibodies, and the specific
targeting of modified antigens in vivo [102]. Therefore, case studies of CD should help in
identifying disease-relevant T-cell epitopes in rheumatoid arthritis.
More specifically, key enzymes catalyzing the post-translational modification of different
amino-acid residues in antigenic structures play a major role both in CD as well as RA— that
is, distinct peptidyl arginine deiminase (PAD) isoforms in RA [104] and TG2 in CD [103]. These
enzymes plus other features shared by CD and RA, include immune targeting of modified
proteins, target organ T-cell infiltration, autoimmune phenomena, HLA association, and the
importance of post-translational modification regarding peptide binding to disease-associated
HLA molecules.
Also, in CD as well as in RA, genome-wide association studies (GWAS) have identified the
HLA region and 26 non-HLA genetic-risk loci. Research has demonstrated that, of the 26 CD
and 26 RA risk loci, six are common to the two disorders, including TAGAP, TNFAIP3, IL2-
IL21, ICOS-CTLA4, REL, and MMEL/TNFRSF14 eliminate, and [105-107]
5. Conclusions
Celiac disease is categorized as an autoimmune disorder. In this context, it is noteworthy that
celiac disease has been associated with various autoimmune disorders, but there are no reliable
data to establish a cause and effect relationship between celiac disease, gluten, and these
autoimmune conditions. In any case, there are more similarities between celiac disease and
typical autoimmune diseases, such as type-1 diabetes and rheumatoid arthritis, than previ‐
ously suspected. It has been proposed that such relationships might be accounted for by the
common pathogenesis that involves similar environmental triggers, genetic predisposition,
and the loss of intestinal barrier secondary to dysfunction of tight junctions leading to greater
gut permeability, and perhaps other mechanisms yet to be discovered.
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